Table 2.

Exome-wide significant genes for serum urate in primary SKAT-O meta-analysis of low-frequency (MAF < 5%) putative damaging variants

	Serum urate						Gout
Race	Number of variants	SKAT-O P-Value	Burden Beta	Burden SE	Burden P-Value	SKAT P-Value	Number of variants	Burden OR	Burden Beta	Burden SE	Burden P-Value
SLC22A12
EA and AA	97	1.3E-56	−0.033	0.002	6.7E-57	3.98E-19	60	0.50	−0.700	0.249	4.93E-03
EA	78	5.1E-42	−0.033	0.002	2.5E-42	1.48E-18	48	0.41	−0.894	0.322	5.52E-03
AA	27	6.4E-16	−0.035	0.004	3.2E-16	8.31E-10	15	0.66	−0.412	0.393	2.94E-01
SLC2A9
EA and AA	90	4.5E-07	−0.004	0.001	2.2E-03	2.27E-07	48	0.85	−0.157	0.116	1.73E-01
EA	71	8.5E-07	−0.006	0.002	1.5E-04	4.25E-07	36	0.78	−0.249	0.142	7.92E-02
AA	28	3.50E-02	−0.001	0.003	6.90E-01	2.00E-02	17	1.03	0.024	0.200	9.03E-01

Exome-wide significant p-value for SKAT-O = 1.28e-6 (= 0.05/19461 genes with 2 or more variants x2 primary SKAT-O tests)

Burden test for gout was conducted using uniform weight for estimating the effect per variant

SE standard error, EA European ancestry, AA African-American, OR odds ratio, SKAT-O optimal sequence kernel association test